Recurrent Ovarian Carcinoma
Showing NaN - NaN of 19
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
Active, not recruiting
- Recurrent Endometrial Endometrioid Adenocarcinoma
- +4 more
-
Anchorage, Alaska
- +584 more
Jan 28, 2023
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial
Active, not recruiting
- Fallopian Tube Clear Cell Adenocarcinoma
- +14 more
- Cediranib
- +9 more
-
Birmingham, Alabama
- +399 more
Dec 30, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +5 more
- Atezolizumab
- +4 more
-
Tucson, Arizona
- +16 more
Oct 19, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Active, not recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Ipilimumab
- Nivolumab
-
Auburn, California
- +205 more
Oct 18, 2022
Metastatic Malignant Solid Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +4 more
- Laboratory Biomarker Analysis
- +4 more
-
Phoenix, Arizona
- +14 more
Sep 1, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma Trial in Canada, Singapore, United States
Active, not recruiting
- Ovarian Brenner Tumor
- +11 more
- Adavosertib
- +5 more
-
Duarte, California
- +15 more
Aug 11, 2022
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma Trial in
Recruiting
- Advanced Differentiated Thyroid Gland Carcinoma
- +102 more
- Cabozantinib S-malate
- Nivolumab
-
Chicago, Illinois
- +2 more
Apr 5, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +44 more
Jan 10, 2022
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Completed
- Fallopian Tube Clear Cell Adenocarcinoma
- +17 more
- Elesclomol Sodium
- Paclitaxel
-
Phoenix, Arizona
- +162 more
Sep 28, 2021
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- +3 more
-
Mobile, Alabama
- +141 more
Jul 22, 2019
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma Trial in United
Completed
- Ovarian Clear Cell Cystadenocarcinoma
- +7 more
- Bevacizumab
- +4 more
-
Aurora, Colorado
- +12 more
Jul 19, 2019
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma Trial in Canada,
Completed
- Adult Hepatocellular Carcinoma
- +44 more
- Bevacizumab
- Temsirolimus
-
Scottsdale, Arizona
- +60 more
Jan 24, 2019
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma Trial in United States (Paclitaxel
Completed
- Fallopian Tube Carcinoma
- +2 more
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation
-
Aurora, Colorado
- +19 more
Dec 14, 2017
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- Rilotumumab
-
Burbank, California
- +27 more
Aug 8, 2017
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Canada, United
Completed
- Recurrent Fallopian Tube Carcinoma
- +5 more
- Gamma-Secretase Inhibitor RO4929097
- Laboratory Biomarker Analysis
-
Beverly Hills, California
- +11 more
Apr 17, 2017
Collecting Tumor Samples From Patients With Gynecological Tumors
Completed
- Borderline Ovarian Clear Cell Tumor
- +85 more
- Laboratory Biomarker Analysis
-
Fayetteville, Arkansas
- +186 more
Oct 26, 2016
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma Trial in United States (3-Dimensional
Completed
- Fallopian Tube Carcinoma
- +4 more
- 3-Dimensional Conformal Radiation Therapy
- +2 more
-
Chicago, Illinois
- +6 more
Feb 10, 2016